UNSPSC 51372118: Dihydrocodeine phosphate

This classification denotes the phosphate form of an opioid receptor agonist and opioid with the molecular formula C18H23NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N9I9HDB855, chemically known as 7, 8-dihydrocodeine but more generally known as dihydrocodeine, which bears US NIH Compound Identifier 3063. European Medicines Agency schedules Dihydrocodeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07138MIG. The term DIHYDROCODEINE is an International Non-Proprietary Name.

UNSPSC 51372118 Dihydrocodeine phosphate is a Commodity code, but the recent state and local opportunities posted under it show little alignment with the code's nominal scope. The three most recent solicitations tag naloxone and safe drug deactivation systems, a direct-to-manufacturer pharmacy initiative, and generic multi-source pharmaceuticals and OTC products — none of which are dihydrocodeine phosphate specifically. The opportunities instead reflect broader pharmaceutical procurement activity: community health agencies acquiring naloxone for overdose response, state health commissions exploring direct contracting models with manufacturers to bypass traditional pharmacy benefit managers, and cooperative purchasing alliances establishing master contracts for generic drugs and OTC items distributed through authorized wholesalers. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing entities (Minnesota Multistate Cooperative Purchasing Alliance).

Activity spans Florida, Texas, and Minnesota. Recent representative opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026; due July 26, 2023, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries), the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026; deadline April 3, 2026, for vendor capabilities in direct-to-manufacturer prescription programs), and MMCAP's RFP S1070000015802 (posted January 20, 2026; due March 26, 2026, for generic multi-source pharmaceuticals and OTC products with awards effective July 1, 2026). The MMCAP solicitation is the most developed, specifying three authorized wholesalers, cGMP and DSCSA compliance, and a 3 percent administrative fee. The code shows substantial pharmaceutical procurement activity, but appears to be tagged inconsistently with its nominal scope — the actual buying is multimodal (naloxone, generics, OTC items, and direct-to-manufacturer models) rather than dihydrocodeine-specific.